Self contained wound dressing apparatus

Information

  • Patent Grant
  • 10384041
  • Patent Number
    10,384,041
  • Date Filed
    Tuesday, April 11, 2017
    7 years ago
  • Date Issued
    Tuesday, August 20, 2019
    5 years ago
Abstract
The composite wound dressing apparatus promotes healing of a wound via the use of a vacuum pump. The vacuum pump applies a vacuum pressure to the wound to effectively draw wound fluid or exudate away from the wound bed. The vacuum pump is tethered to the wound dressing and is portable, preferably, carried by the patient in a support bag, which permits patient mobility. Moreover, the patient does not need to be constrained for any period of time while exudate is being removed from the wound.
Description
BACKGROUND

Technical Field


The present disclosure relates to an apparatus for treating an open wound, and, more specifically, relates to a self-contained wound dressing with a portable pump system which draws wound fluids into a collection canister supported by the patient.


Description of Related Art


Wound closure involves the migration of epithelial and subcutaneous tissue adjacent the wound towards the center of the wound until the wound closes. Unfortunately, closure is difficult with large wounds or wounds that have become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound. Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but, are also less able to successfully fight microbial infection and, thus, are less able to close the wound naturally. Such wounds have presented difficulties to medical personnel for many years.


Wound dressings have been used in the medical industry to protect and/or facilitate healing of open wounds. One popular technique has been to use negative pressure therapy, which is also known as suction or vacuum therapy. A variety of negative pressure devices have been developed to allow excess wound fluids, i.e., exudates to be removed while at the same time isolating the wound to protect the wound and, consequently, effect recovery time. Various wound dressings have been modified to promote the healing of open wounds.


Issues that continually need to be addressed when using a wound dressing include ease of use, efficiency of healing a wound, portability and negative pressure control capabilities. Thus, there remains a need to constantly improve negative pressure wound dressings for open wounds.


SUMMARY

In accordance with a preferred embodiment, a wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed, a portable vacuum pump in fluid communication with the wound dressing member for applying subatmospheric pressure to facilitate removal of fluid from the wound dressing member, and being be carried by the body of a patient, and a collection canister carried by the body of the patient and in fluid communication with the vacuum pump for collecting fluids removed from the wound dressing member. Preferably, the vacuum source includes a peristaltic vacuum pump and is adapted to produce subatmospheric pressure ranging between about 20 mmHg and about 500 mmHg, more preferably, about 75 mmHg to about 125 mmHg. The collection canister may include an absorbent material to contain the fluid removed from the wound dressing member. Preferably, the apparatus also include a body support bag which is adapted for mounting to the patient. The body support bag may have a pouch for retaining at least one of the collection canister and vacuum pump.


The vacuum pump preferably includes control means to control operation thereof. A pressure sensor may be incorporated with the control means to detect pressure at a predetermined location relative to the wound dressing member, and send a corresponding signal to the control means. The control means may include a controller adapted to control or vary the output of the vacuum source. The vacuum pump preferably includes a self-contained battery.


The preferred wound dressing member includes a lower member positionable adjacent the wound bed, an upper absorbent member positionable adjacent the lower member, and a top member. The upper absorbent member comprises a material selected from the group consisting of foams, nonwoven composite fabrics, cellulosic fabrics, super absorbent polymers, and combinations thereof. The upper absorbent member may also include at least one of a medicament, an anti-infective agent, an antimicrobial, polyhexamethylene biguanide (hereinafter, “PHMB”), antibiotics, debridement agents, analgesics, healing factors, vitamins, growth factors and nutrients.


In another preferred embodiment, a wound dressing apparatus, includes a wound dressing member dimensioned for positioning relative to a wound bed, a portable vacuum pump in fluid communication with the wound dressing member for applying subatmospheric pressure to facilitate removal of fluid from the wound dressing member, and having a self contained battery for operating the vacuum pump, a collection canister in fluid communication with the vacuum pump for collecting fluids removed from the wound dressing member and a body support bag attachable to the body of the patient and having a pouch for retaining at least one of the collection canister and the vacuum pump.


A method for facilitating healing of a wound is also disclosed. The method includes the steps of positioning a wound dressing member relative to a wound bed, introducing a portable vacuum pump to be in fluid communication with the wound dressing member for applying subatmospheric pressure to facilitate removal of fluid from the wound dressing member, connecting a collection canister in fluid communication with the vacuum pump for collecting fluids removed from the wound dressing member, mounting a body support bag having a retaining pouch and positioning at least one of the collection canister and the vacuum pump into the retaining pouch of the body support bag.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the subject wound dressing are described herein with reference to the drawings wherein:



FIG. 1 is a partial cross-sectional view of a self contained wound dressing apparatus in accordance with the principles of the present disclosure illustrating the wound dressing member, pump system and collection canister;



FIG. 1A is a cross-sectional view taken along the lines 1A-1A of FIG. 1 illustrating the vacuum tube of the wound dressing apparatus;



FIG. 2 is a schematic view of the pump system;



FIG. 3 is a view illustrating a body support bag for containing the collection canister and/or pump system;



FIG. 4 is a view illustrating an alternate embodiment of the body support bag of FIG. 3; and



FIG. 5 is a view illustrating an alternate embodiment of the self contained wound dressing apparatus.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The composite wound dressing apparatus of the present disclosure promotes healing of a wound via the use of an external peristaltic vacuum pump. The external peristaltic pump applies a vacuum pressure to the wound to effectively draw wound fluid or exudate away from the wound bed. The external peristaltic pump is tethered to the wound dressing and is portable, preferably, carried by the patient, which permits patient mobility. Moreover, the patient does not need to be constrained for any period of time during therapy and while exudates is being removed from the wound.


Referring now to FIG. 1, the wound dressing apparatus 100 in accordance with a preferred embodiment of the present disclosure is illustrated. Wound dressing apparatus 100 includes composite wound dressing 102 and pump system 104 tethered to the wound dressing 102. Wound dressing 102 is in the form of an article with multiple layers arranged in juxtaposed or superposed relation. The multiple layers include, but are not limited to a base layer 106, a packing/absorbent layer 108, and a non-porous adherent top layer 110.


The base layer 106 is in direct contact with the wound bed “w”. The base layer 106 is typically porous and non-adherent. “Non-adherent” as used herein refers to a material that does not adhere to tissues in and around the wound bed. “Porous” as used herein refers to a material which contains numerous small perforations or pores which allow wound fluids of all kinds to pass through the material to the dressing layers above. The passage of wound fluid through the porous material is preferably unidirectional such that wound exudate does not flow back to the wound bed. This direction flow feature could be in the form of directional apertures imparted into the material layer, a lamination of materials of different absorption to the base layer 106 or specific material selection that encourages directional flow. Exemplary materials used as the base layer 106 include a contact layer sold under the trademark XEROFLO® by Kendall Corp, a division of TycoHealthcare.


In addition, agents such as hydrogels and medicaments could be bonded or coated to the base layer 106 to reduce bioburden in the wound, promote healing and reduce pain associated with dressing changes or removal. Medicaments include, for example, antimicrobial agents, growth factors, antibiotics, analgesics, and the like. Furthermore, when an analgesic is used, the analgesic could include a mechanism that would allow the release of that agent prior to dressing removal or change.


The layer proximal to the base layer 106 is the packing/absorbent layer 108. The packing/absorbent layer 108 is intended to absorb and capture wound fluid and exudates. Exemplary materials used as the packing/absorbent layer 108 include the antimicrobial dressing sold under the trademark KERLIX® by Kendall Corp., a division of TycoHealthcare. Those skilled in the art will recognize that the packing/absorbent layer 108 can be formed into any suitable shape. The only requirement as to shape is that the packing/absorbent layer 108 is suitable to conform to a particular shape of the wound.


A further use for the packing/absorbent layer 108 is to decrease the incidence of infection in the wound bed. Hence, the packing/absorbent layer 108 may be treated with medicaments. Medicaments include, for example, an anti-infective agent such as an antiseptic or other suitable antimicrobial or combination of antimicrobials, polyhexamethylene biguanide (hereinafter, “PHMB”), antibiotics, analgesics, healing factors such as vitamins, growth factors, nutrients and the like, as well as a simple flushing with isotonic saline solution.


With continued reference still to FIG. 1, the top layer 110 encompasses the perimeter of the wound dressing 102 to surround the wound bed “w” to provide an occlusive seal around the perimeter of the wound bed “w”. The top layer 110 may include an adhesive bonded to an area that surrounds the wound bed “w” or may incorporate an additional layer which has the adhesive. The adhesive must provide acceptable adhesion to the tissue “t” surrounding the wound bed “w” skin, e.g., the periwound area, and be acceptable for use on skin without contact deterioration (for example, the adhesive should preferably be non-irritating and non-sensitizing.) The adhesive may be semi-permeable to permit the contacted skin to breathe and transmit moisture. Alternatively, the adhesive may be impermeable. Additionally, the adhesive could be activated or de-activated by an external stimulus such as heat or a given fluid solution or chemical reaction. Adhesives include, for example, the ULTEC Hydrocolloid Dressing, by Kendall Corp., a division of TycoHealthcare.


The top layer 110 is preferably in the form of a sheet mounted proximal to the packing/absorbent layer 108. In a preferred embodiment, the peripheral portions 110P of the top layer 110 includes an adhesive and is secured to the tissue “t” about the wound bed “w”. The peripheral portions 110P may be secured to the periphery of base layer 102 if desired. It is anticipated that removable liners may also be used to protect the adhesive surface of the top layer 110 prior to use.


The top layer 110 may incorporate a flexible material, e.g., resilient or elastomeric, that seals the top of the wound dressing 102. In one embodiment, the top layer 110 includes the transparent dressing manufactured under the trademark Polyskin II® by Kendall Corp, a division of TycoHealthcare. POLYSKIN® II is a transparent, semi-permeable material which permits moisture and oxygen exchange with the wound site, and provides a barrier to microbes and fluid containment. In the alternative, the top layer 110 may be impermeable. The transparency of the top layer 110 provides a visual indication of the status of the wound dressing and more particularly, the status of the saturation level of the layers of the wound dressing. The top layer 110 further includes a vacuum port or connector 112 in fluid communication with the interior of the wound dressing 102. The vacuum port 112 may be a separate component attached to the top layer 110 and connected thereto by conventional means or integrally formed with the top layer 110. The vacuum port 112 may have a valve built therein, e.g., a one way valve, to permit exudates to flow in one direction only, i.e., away from the wound dressing 102 toward the pump system 104. Vacuum port 112 is adapted to be releasably connected to the pump system 104 as will be discussed and may or may not include structure for releasable connection to the pump system.


Referring still to FIG. 1, the pump system 104 will be discussed. The pump system 104 includes a vacuum source 114, inlet tubing 116 connecting the inlet side of the vacuum source 114 to the vacuum port 112 of the wound dressing 102 and a collector canister 118 connected to the outlet side of the vacuum source 114 by outlet tubing 120. In the alternative, the collection canister 118 may be disposed “in-line” between the vacuum source 114 and the wound dressing 102. Vacuum source 114 may be any type of pump that is biocompatible and maintains or draws adequate and therapeutic vacuum levels. Preferably, the vacuum level to be achieved is in a range between about 20 mmHg and about 500 mmHg, more preferably, about 75 mmHg and about 125 mmHg. The pump 114 may be removable, reusable, and/or rechargeable. Typically, the pump 114 is a pump of the diaphragmatic or peristaltic type, or the like, in which the moving part(s) draw exudate out of the wound bed into the wound dressing by creating areas or zones of decreased pressure e.g., vacuum zones with the wound dressing 102. This area of decreased pressure preferably communicates with the wound bed “w” to facilitate removal of the fluids therefrom and into the packing/absorbent layer 108. The pump 114 may be actuated by any means known by those skilled in the art. In a preferred embodiment of the present disclosure, the pump 114 is a peristaltic pump. One suitable peristaltic pump is the Kangaroo PET Enternal Feeding Pump manufactured by Kendall Corp., a division of TycoHealthcare. Another suitable peristaltic pump may be the model 101 V/R pmy MK2 manufactured by Watson Marlow LTD of England. Preferably, the peristaltic pump produces subatmospheric pressure ranging from about 20 mmHg to about 500 mmHg. A suitable diaphragm pump includes model NMP 850 KNDC manufactured by KNF Neuberger of Germany.


The inlet and outlet tubings 116,120 may be any suitable flexible tubing fabricated from elastomeric and/or polymeric materials. The inlet tubing 116 is preferably releasably connected to the vacuum port 112 through conventional means including a friction fit, bayonet coupling, snap fit or the like. The collection canister 118 may be any flexible disposable pouch or the like. The collection canister 118 may include a super absorbent material such as superabsorbent polymers (SAP), silica gel, sodium polyacrylate, potassium polyacrylamide and related compounds to consolidate or contain wound drainage or debris. The collection canister 118 is preferably transparent to permit viewing into the interior of the canister 118 to assist the patient in determining the remaining capacity of the collection canister 118 and quality of exudates.


Referring to FIG. 2, the pump system 104 preferably includes an internal self contained battery source 122, a pressure sensor or transducer 124 to monitor pressure within the wound dressing, and self-contained regulation or control means 126. The pressure sensor 124 is preferably disposed within the interior of the wound dressing 102 and is in electrical connection with the control means 126 through an electrical wiring 128. (FIG. 1) One suitable pressure sensor is the Dynamic ICP Pressure Sensor of the Pressure Division of PCB Piezotronics, Inc. The pressure sensor 124 would also provide information to assist in detecting a leak in the wound dressing 102. The electrical wiring 128 may be passed through the vacuum port 112 and through inlet tubing 116 or on the exterior surface of the inlet tubing 116. Alternatively, the electrical wiring 128 may pass through a conduit or channel in the wall of the vacuum port 112 and/or the inlet tubing 116. FIG. 1A illustrates the various arrangements where the electrical wiring 128 passes through the channel of the tubing 116 or the central lumen of the tubing 116. The control means 126 is preferably incorporated within the pump housing of the pump 114. The control means 126 may incorporate a motor controller/driver 130 including processing and drive software or circuitry to control or vary the drive voltage to the motor of the pump 114 responsive to the pressure sensed by the pressure sensor 124 and/or other operational parameters including operational time constraints etc. For example, the motor controller/driver may be programmed to run only for a predetermined period of time after start-up. The output of the motor of the pump 114 may be increased or decreased, or initiated or discontinued, as controlled by the control means 126. The regulation or control means 126 may also have an alarm such as a visual, audio or tactile sensory alarm (e.g., vibratory etc.) to indicate to the patient when specific conditions have been met (e.g., the desired vacuum level, loss of vacuum or leak). An override switch 130 may also be incorporated within the pump system to permit the patient to optionally initiate or terminate operation of the pump as desired without input from the control means 126. Wireless means are also envisioned to operate the pump 114 through the control means 126.


With reference now to FIG. 3, there is illustrated a body support bag 134 for supporting at least the canister and/or the pump 114. As discussed, the pump system 104 is adapted for mounting to the body of the patient to be a self contained portal unit. In this regard, the pump system 104 may be at least partially carried or supported by the body support bag 134. The body support bag 134 generally includes a pouch 136 and at least one strap 138, preferably two straps, for securing the pouch 136 to the body of the patient. The body support bag 134 is intended to receive and store at least the collection canister 118 and/or the pump 114. The body support bag 134 may be worn about the waist of the patient. This is desirable in that it may reduce the length of tubing needed depending on the location of the wound. In addition, the pouch 136 may be located adjacent the abdomen of the patient which may present a significantly enhanced ability to conceal the system. The inlet and outlet tubings 116,120 may be secured to the body with tape or the like, or, optionally, may be unsecured and disposed beneath the patient's clothing. Thus, the body support bag 134 permits the patient to move without restrictions or limitations, and provides an entirely portable capability to the patient during wound drainage and healing.



FIG. 4 illustrates an alternate embodiment of the body support bag. In accordance with this embodiment, the body support bag 140 is adapted for mounting to the shoulder of the patient and has a pouch 142. In other respects, the body support bag 140 functions in a similar manner to the body support bag of FIG. 3.


In use, the wound dressing apparatus 100 is positioned within the wound bed “w” as shown in FIG. 1 and secured about the wound “w” in the manner discussed hereinabove. The pump 114 and/or collection canister 118 are positioned within the pouch 136 of the body support bag 134 (or support bag 140). The body support bag 134, 140 is mounted to the patient either about the waist, shoulder, leg, etc. . . . with the straps 134. The inlet and outlet tubings 114,120 may be secured to the patient's body with tape or the like. Thereafter, the pump 114 is initiated to create a zone of subatmospheric pressure (i.e., a state of vacuum) within the wound dressing 100. The pump 114 may be initiated via the manual override switch 130, or may be started via the pressure sensor 124 which detects the lack of subatmospheric pressure within the wound dressing apparatus 100 and sends a corresponding signal to the control means 126. The control means 126, in turn, activates the pump 114. As the subatmospheric pressure within the wound dressing 102 increases, the top layer 110 and packing/absorbent layer 108 may collapse. Fluids are drawn away from the wound bed “w” and into the packing/absorbent layer 106 of the wound dressing 102. These fluids and/or exudates may be removed from the packing/absorbent layer 106 under the negative pumping energy of the pump 114. The fluids are delivered through the inlet and outlet tubings 116,120 to be collected within the collection canister 118. Once the desired level of subatmospheric pressure is achieved as detected by, e.g., the pressure sensor 124, the pressure sensor 124 sends a signal to the control means 126. The control means 126 may either terminate operation of the pump 114 or alternatively vary the speed or output (e.g., decrease) of the pump 114. In this vacuum state, wound fluid and exudates are continually drawn into the packing/absorbent layer 106. After a period of time, the wound dressing 102 may lose its vacuum state as detected by the pressure sensor 124 or detected visually by the patient. When the loss of a desired vacuum level is achieved, the pressure sensor 124 sends a signal to the control means 126 to activate or increase the output of the pump 114. The pump 114 removes the fluid from the packing/absorbent layer 108 and reestablishes the vacuum state within the wound dressing 102. As indicated hereinabove, in the alternative, the pump 114 may be initiated via the manual override switch 130 when e.g., the patient sees that the collection canister 118 is full. This process may continue several times during wound healing during one application or a series of applications.


Once the wound is fully healed, the wound closure apparatus and pump system may be disposed. The body support bag may also be disposed or cleaned for subsequent use. The pump may be sterilized and reused as well.



FIG. 5 illustrates another embodiment of the present disclosure. In accordance with this embodiment, wound dressing apparatus 200 includes micropump 202 which is adapted for mounting within absorbent layer 204. Micropump 202 has a length ranging from about 1 to 3 inches and a relatively small diameter, preferably, no greater than about one inch. The micropump 202 may be any type of pump that is biocompatible and maintains or draws adequate and therapeutic vacuum levels. The micropump 202 may be removable, reusable, and/or rechargeable. The micropump 202 may be a pump of the diaphragmatic, peristaltic or rotary type, or the like, in which the moving part(s) draw exudates out of the wound bed into the wound dressing by creating areas or zones of decreased pressure e.g., vacuum zones with the wound dressing apparatus 200. This area of decreased pressure preferably communicates with the wound bed “w” to facilitate removal of the fluids therefrom and into the absorbent layer 204. The micropump 202 may be actuated by any means known by those skilled in the art. In a preferred embodiment of the present disclosure, the micropump 202 is a peristaltic pump. One suitable micropump is manufactured by Piab Vacuum Products in Hingham, Mass. Preferably, the peristaltic pump produces subatmospheric pressure ranging from about 20 mmHg to about 500 mmHg.


Absorbent layer 204 is preferably a foam filled dressing which is transparent. The foam may be a resilient, liquid absorbent, porous, polymer-based foam. The foam may be a dispensable liquid which at least partially solidifies to a crystal-like arrangement defining hollow tubes to allow exudates drainage. The foam is dispensed within the wound bed and is potentially collapsible to expel air from the foam channels. The foam may be an expandable hydrophilic foam which is capable of absorbing fluid from a wound and maintain the wound bed moist. The hollow tubes or voids defined by the foam also provide a means to conduct electricity, heat, cold, and ultrasound. The hollow tubes or voids also provide a bioactive scaffold for tissue growth. A thin film transparent top layer 205 is secured about the wound area to enclose the wound.


The self contained battery source and control circuitry may be mounted within housing 206 which is connected to belt 208. Belt 208 is adapted for mounting to the body of a patient, e.g., around the waist area and may include VELCRO® means for securing about the patient. Belt 208 may further support canister 210 which receives the fluid exudates from pump 202 through tube 212. Tube 214 extends from housing 206 to pump 202 and may incorporate electronic wires etc. for operating the pump. In the alternative, tube 212 may incorporate the electrical wires within, e.g., a lumen, and extend from the housing to pump 202 and canister 210.


It is further contemplated that the wound dressing apparatus may incorporate external means or applications to stimulate tissue growth and/or healing. For example, an auxiliary treatment apparatus may be incorporated into the wound dressing apparatus to impart electrical or mechanical energy for the treatment of the tissue such as, for instance, directing electrical, thermal or vibratory energy on the wound area and/or introducing various drugs into the human body through the skin. The auxiliary treatment apparatus may be incorporated into the housing of the pump 202 as shown schematically as reference numeral 216 and operated via a control means discussed hereinabove. One suitable auxiliary treatment apparatus may include an ultrasonic transducer. Other sensor types are also contemplated for incorporation into the wound dressing apparatus including oxygen, chemical, microbial and/or temperature sensors. The detection of oxygen adjacent the wound area would assist the clinician in determining the status of wound healing. The presence of an elevated temperature may be indicative of an infection. The pump system may incorporate circuitry to communicate with a computer, e.g., a hand-held PALM® device through wireless means.


While the disclosure has been illustrated and described, it is not intended to be limited to the details shown, since various modifications and substitutions can be made without departing in any way from the spirit of the present disclosure. For example, it is envisioned that the subject matter of the commonly assigned U.S. patent application Ser. No. 11/517,210, filed on Sep. 6, 2006, which claims priority to Provisional Application No. 60/714,812, filed on Sep. 6, 2005, now issued as U.S. Pat. No. 7,569,742 on Aug. 4, 2009, and the subject matter of the commonly assigned U.S. patent application Ser. No. 11/516,925, filed on Sep. 6, 2006, which claims priority to Provisional Application No. 60/714,805, filed on Sep. 7, 2005, now issued as U.S. Pat. No. 7,699,823 on Apr. 20, 2010 (the entire contents of each application being incorporated herein) may be incorporated into the present disclosure. As such, further modifications and equivalents of the invention herein disclosed can occur to persons skilled in the art using no more than routine experimentation, and all such modifications and equivalents are believed to be within the spirit and scope of the disclosure as defined by the following claims.

Claims
  • 1. A negative pressure wound therapy apparatus comprising: a wound dressing configured to enclose a wound and provide a seal around a perimeter of the wound, the wound dressing comprising a first layer and a second layer arranged in superposed relation, the first layer configured to absorb and capture wound fluid and the second layer positioned over the first layer;a pump system comprising: a vacuum pump configured to apply vacuum pressure to the wound to draw wound fluid away from the wound, wherein the vacuum pump is positioned within the wound dressing;a pressure sensor configured to detect pressure within the wound dressing, the pressure sensor positioned within the wound dressing;a controller configured to control the vacuum pump,wherein the pump system is configured to communicate wirelessly with an external electronic device.
  • 2. The apparatus of claim 1, wherein the controller is configured to wirelessly communicate with an external computer.
  • 3. The apparatus of claim 1, wherein the controller is configured to control the vacuum pump in response to a pressure sensed by the pressure sensor.
  • 4. The apparatus of claim 1, wherein the wound dressing further comprises a wound contact layer configured to be in direct contact with the wound.
  • 5. The apparatus of claim 4, wherein the wound contact layer includes a plurality of pores configured to allow unidirectional flow of the wound fluid toward the first layer when vacuum pressure is applied to the wound.
  • 6. The apparatus of claim 4, wherein the wound contact layer includes medicament coated thereto.
  • 7. The apparatus of claim 1, wherein the controller comprises an override switch configured to initiate or terminate operation of the vacuum pump without input from the pressure sensor.
  • 8. The apparatus of claim 1, wherein the first layer comprises an absorbent material.
  • 9. The apparatus of claim 8, wherein the absorbent material comprises a material selected from the group consisting of foams, nonwoven composite fabrics, cellulosic fabrics, super absorbent polymers, and combinations thereof.
  • 10. The apparatus of claim 8, wherein the absorbent material comprises at least one of a medicament, an anti-infective agent, an antimicrobial, polyhexamethylene biguanide, antibiotics, analgesics, healing factors, vitamins, growth factors and nutrients.
  • 11. The apparatus of claim 1, wherein the second layer comprises a transparent material.
  • 12. The apparatus of claim 11, wherein the transparent material is configured to allow a visual indication of the status of the wound dressing.
  • 13. The apparatus of claim 1, wherein the pump system is configured to communicate to the external electronic device at least one of: establishment of a desired vacuum level, loss of vacuum, or a leak.
  • 14. A method of operating a negative pressure wound therapy apparatus, the method comprising: by a negative pressure source positioned within a wound dressing, applying negative pressure to a wound covered by the wound dressing that comprises a first layer and a second layer arranged in superposed relation, the first layer configured to absorb and capture wound fluid and the second layer positioned over the first layer;by a pressure sensor positioned within the wound dressing, detecting pressure within the wound dressing; andwirelessly communicating with an external electronic device.
  • 15. The method of claim 14, further comprising controlling the negative pressure source based the detected pressure.
  • 16. The method of claim 14, further comprising wirelessly communicating to the external electronic device at least one of: establishment of a desired vacuum level, loss of vacuum, or a leak.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/866,346, filed on Apr. 19, 2013, now U.S. Pat. No. 9,629,986, which is a continuation of U.S. patent application Ser. No. 12/879,715, filed Sep. 10, 2010, now U.S. Pat. No. 8,444,612, which is a continuation of U.S. patent application Ser. No. 11/516,216 filed on Sep. 6, 2006, which claims priority to U.S. Provisional Patent Application Ser. No. 60/714,912, filed on Sep. 7, 2005. The priority of these prior applications is expressly claimed and their disclosures are hereby incorporated by reference in their entirety.

US Referenced Citations (224)
Number Name Date Kind
3367332 Groves Feb 1968 A
3520300 Flower, Jr. Jul 1970 A
3874387 Barbieri Apr 1975 A
3972328 Chen Aug 1976 A
4224941 Stivala Sep 1980 A
4398910 Blake et al. Aug 1983 A
4624656 Clark et al. Nov 1986 A
4664662 Webster May 1987 A
4681562 Beck et al. Jul 1987 A
4710165 McNeil et al. Dec 1987 A
4969880 Zamierowski Nov 1990 A
5055195 Trasch et al. Oct 1991 A
5055198 Shettigar Oct 1991 A
5056510 Gilman Oct 1991 A
5060642 Gilman Oct 1991 A
5086763 Hathman Feb 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5152757 Eriksson Oct 1992 A
5176663 Svedman et al. Jan 1993 A
5181905 Flam Jan 1993 A
5238732 Krishnan Aug 1993 A
5261893 Zamierowski Nov 1993 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5636643 Argenta et al. Jun 1997 A
5643189 Masini Jul 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5733337 Carr et al. Mar 1998 A
5759570 Arnold Jun 1998 A
5779657 Daneshvar Jul 1998 A
5833646 Masini Nov 1998 A
5911222 Lawrence et al. Jun 1999 A
6071267 Zamierowski Jun 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6168800 Dobos et al. Jan 2001 B1
6174306 Fleischmann Jan 2001 B1
6183438 Berguer Feb 2001 B1
6225523 Masini May 2001 B1
6261276 Reitsma Jul 2001 B1
6261283 Morgan et al. Jul 2001 B1
6287521 Quay et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6442413 Silver Aug 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
6557704 Randolph May 2003 B1
6599262 Masini Jul 2003 B1
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6681003 Linder et al. Jan 2004 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6787682 Gilman Sep 2004 B2
6794554 Sessions et al. Sep 2004 B2
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6855860 Ruszczak et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
7022113 Lockwood et al. Apr 2006 B2
7067709 Murate et al. Jun 2006 B2
7077832 Fleischmann Jul 2006 B2
7087806 Scheinberg et al. Aug 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128735 Weston Oct 2006 B2
7216651 Argenta et al. May 2007 B2
7279612 Heaton et al. Oct 2007 B1
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7524315 Blott et al. Apr 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7611500 Lina et al. Nov 2009 B1
7615036 Joshi et al. Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645253 Gura et al. Jan 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7708724 Weston May 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7896864 Lockwood et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922676 Daskal et al. Apr 2011 B2
7922703 Riesinger Apr 2011 B2
7942866 Radl et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8100887 Weston et al. Jan 2012 B2
8118794 Weston Feb 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8212100 Moore Jul 2012 B2
8282611 Weston Oct 2012 B2
8303552 Weston Nov 2012 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8529548 Blott et al. Sep 2013 B2
8545464 Weston Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8628505 Weston Jan 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
9168330 Joshi et al. Oct 2015 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20010051781 Augustine et al. Dec 2001 A1
20020065494 Lockwood et al. May 2002 A1
20020115952 Johnson et al. Aug 2002 A1
20020128578 Johnson Sep 2002 A1
20020128804 Geva Sep 2002 A1
20020135336 Zhou et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030009244 Engleson et al. Jan 2003 A1
20030040687 Boynton et al. Feb 2003 A1
20030078532 Ruszczak et al. Apr 2003 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030097100 Watson May 2003 A1
20030105649 Sheiner et al. Jun 2003 A1
20030208149 Coffey Nov 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040006319 Lina Jan 2004 A1
20040019464 Martucci et al. Jan 2004 A1
20040030304 Hunt Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040054338 Bybordi Mar 2004 A1
20040054775 Poliac et al. Mar 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040073151 Weston Apr 2004 A1
20040078223 Sacco et al. Apr 2004 A1
20040087884 Haddock et al. May 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040143458 Pulkkinen Jul 2004 A1
20040167482 Watson Aug 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20040249353 Risk, Jr. et al. Dec 2004 A1
20040260230 Randolph Dec 2004 A1
20050004534 Lockwood et al. Jan 2005 A1
20050010153 Lockwood et al. Jan 2005 A1
20050012616 Forster et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050033124 Kelly et al. Feb 2005 A1
20050058694 Nielsen Mar 2005 A1
20050065471 Kuntz Mar 2005 A1
20050070835 Joshi Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050090787 Risk, Jr. et al. Apr 2005 A1
20050114176 Dominick et al. May 2005 A1
20050119737 Bene et al. Jun 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050147562 Hunter et al. Jul 2005 A1
20050222528 Weston Oct 2005 A1
20050240111 Chung Oct 2005 A1
20060029650 Coffey Feb 2006 A1
20060069365 Sperl et al. Mar 2006 A1
20060107642 Smith et al. May 2006 A1
20060155260 Blott et al. Jul 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060224051 Teller et al. Oct 2006 A1
20060225787 Newrones et al. Oct 2006 A1
20060228057 Newrones et al. Oct 2006 A1
20060246922 Gasbarro et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20070055209 Patel et al. Mar 2007 A1
20070128055 Lee Jun 2007 A1
20070179460 Adahan Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20080009681 Hussiny Jan 2008 A1
20080051716 Stutz Feb 2008 A1
20080306456 Riesinger Dec 2008 A1
20090012484 Nielsen et al. Jan 2009 A1
20100160880 Weston Jun 2010 A1
20110009835 Blott Jan 2011 A1
20110028918 Hartwell Feb 2011 A1
20110054421 Hartwell Mar 2011 A1
20110087178 Weston Apr 2011 A2
20110118683 Weston May 2011 A1
20110172615 Greener Jul 2011 A2
20120157942 Weston Jun 2012 A1
20130267921 Weston Oct 2013 A1
20130274688 Weston Oct 2013 A1
20130331822 Patel Dec 2013 A1
20150065965 Haggstrom Mar 2015 A1
20160058927 Weston Mar 2016 A1
20180028729 Joshi et al. Feb 2018 A1
Foreign Referenced Citations (53)
Number Date Country
198 44 355 Apr 2000 DE
20 2004 017 052 Jul 2005 DE
0 512 543 Nov 1992 EP
0 853 950 Jul 1998 EP
1 088 569 Apr 2001 EP
1 219 311 Jul 2002 EP
1 922 044 Apr 2011 EP
2 021 046 Mar 2012 EP
2 603 699 Jun 2013 EP
1 684 146 Jul 2014 EP
3 072 542 Sep 2016 EP
3 062 751 Aug 2017 EP
3 257 486 Dec 2017 EP
1163907 Oct 1958 FR
2 939 320 Jun 2010 FR
2 307 180 Nov 1996 GB
2 329 127 Mar 1999 GB
2 336 546 Oct 1999 GB
2 307 180 Jun 2000 GB
2 344 531 Jun 2000 GB
2 415 908 Jan 2006 GB
2511523 Sep 2014 GB
H04-354722 Dec 1992 JP
2002-0032508 May 2002 KR
131622 Aug 2013 RU
WO 199101706 Feb 1991 WO
WO 1993009727 May 1993 WO
WO 199319710 Oct 1993 WO
WO 199420041 Sep 1994 WO
WO 199605873 Feb 1996 WO
WO 200021586 Apr 2000 WO
WO 2001037922 May 2001 WO
WO 2003005943 Jan 2003 WO
WO 2003018098 Mar 2003 WO
WO 2003030966 Apr 2003 WO
WO 2003045492 Jun 2003 WO
WO 2003057070 Jul 2003 WO
WO 2003057071 Jul 2003 WO
WO 2003057307 Jul 2003 WO
WO 2003086232 Oct 2003 WO
WO 2003092620 Nov 2003 WO
WO 2003094090 Nov 2003 WO
WO 2003101508 Dec 2003 WO
WO 2004018020 Mar 2004 WO
WO 2004071279 Aug 2004 WO
WO 2005009488 Feb 2005 WO
WO 2005025447 Mar 2005 WO
WO 2005109297 Nov 2005 WO
WO 2005115497 Dec 2005 WO
WO 2005123170 Dec 2005 WO
WO 2007030599 Mar 2007 WO
WO 2009066104 May 2009 WO
WO 2009124125 Oct 2009 WO
Non-Patent Literature Citations (26)
Entry
European Examination Report, re EP Application No. 06803097.2, dated May 8, 2012.
European Examination Report, re EP Application No. 06803097.2, dated Nov. 3, 2011.
European Examination Report, re EP Application No. 14200239.3, dated May 6, 2015.
KCI, “V.A.C. Freedom User's Guide”, May 2002, in 16 pages.
KCI Licensing, Inc., “V.A.C Drape Instructions for Use”, Oct. 2003, in 2 pages.
Kendall ULTEC Hydrocolloid Dressing (4″x4″), product ordering page, web page downloaded Jul. 13, 2014.
Notice of Opposition—Statement of Facts and Evidence re EP 2 708 216 dated Jan. 5, 2017, in 18 pages.
Membrane Filters, in 17 pages, from website: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11 (date unknown, but believed to be copyright 2001-2011).
Protz, Kerstin: “Modern Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation and Anwendung, Geriatrie Journal Apr. 2005, pp. 3333-3339.
Brief Communications and Accompanying Filed Items, re European Patent No. 2 708 216, dated Apr. 11, 2018, in 48 pages.
International Search Report and Written Opinion, re PCT Application No. PCT/US2006034825, dated Apr. 16, 2007.
International Preliminary Report on Patentability, re PCT Application No. PCT/US2006/034825, dated Mar. 11, 2008.
Interlocutory Decision in Opposition and Accompanying Items, re European Patent No. 2 708 216, dated Jun. 27, 2018, in 29 pages.
Nullification of the German part of European patent 2 021 046 (German file references 60 2007 021 330.4), dated Nov. 23, 2015, with translation.
Provision of the Minutes, re European Patent No. 2 708 216, dated Jun. 27, 2018, in 5 pages.
Written Submission in Preparation to Oral Proceedings and Accompanying Filed Items, re European Patent No. 2 708 216, dated Apr. 5, 2018, in 42 pages.
Written Submission in Preparation to Oral Proceedings and Accompanying Items, re European Patent No. 2 708 216, filed Apr. 6, 2018 (dated Apr. 5, 2018), in 178 pages.
Written Submission in Preparation to Oral Proceedings and Accompanying Items, re European Patent No. 2 708 216, dated Apr. 19, 2018, in 64 pages.
Written Submission in Preparation to Oral Proceedings and Accompanying Items, re European Patent No. 2 708 216, dated Jun. 5, 2018, in 77 pages.
Annex to the Summons, re European Patent No. EP 2 708 216, dated Oct. 30, 2017, in 6 pages.
Reply of the Patent Proprietor to the Notice of Opposition, re European Patent No. EP 2 708 216, dated Jun. 20, 2017, in 4 pages.
Main request during Opposition procedure, re European Patent No. EP 2 708 216, dated Jun. 20, 2017, in 2 pages.
Amended Claims with Annotations, re European Patent No. EP 2 708 216, dated Jun. 20, 2017, in 2 pages.
Notice of Appeal and subsequently filed items, re European U.S. Pat. No. 2 708 216, dated Aug. 13, 2018, in 4 pages.
Reply to Appeal and subsequently filed items, re European U.S. Pat. No. 2 708 216, dated Mar. 8, 2019, in 116 pages.
Statement of Grounds of Appeal and subsequently filed items, re EP 2 708 216, dated Oct. 23, 2018, in 260 pages.
Related Publications (1)
Number Date Country
20170259047 A1 Sep 2017 US
Provisional Applications (1)
Number Date Country
60714912 Sep 2005 US
Continuations (3)
Number Date Country
Parent 13866346 Apr 2013 US
Child 15484622 US
Parent 12879715 Sep 2010 US
Child 13866346 US
Parent 11516216 Sep 2006 US
Child 12879715 US